drugset / Trial / NCT07806292
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
Timeline
- Start
- 2025-04-28
- Primary completion
- 2026-12-31
- Completion
- 2027-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |